The trial is currently aiming to recruit 640 patients. Each cohort will include a maximum of 30 patients, and some cohorts may fill up quicker than others if the gene changes that they target are more common in the patient population.
As the trial goes on, the research team may identify other drugs that they think could work for patients with other gene changes. If this happens, new Arms will be added to the trial and the number of patients in the trial will increase.
A group called the Trial Steering Committee will review the trial data at certain points, and may decide to suspend recruitment or remove an Arm or Cohort from the trial if it is not effective.